INDEX TO NUMBER 1

A

Acupuncture analgesia, mediation by opioid peptides, 97
Adenosine 3′5′ cyclic monophosphate, effect on opiates, 55
Adrenal medulla, enkephalin in, 74
Adrenocorticotrophic hormone, effect of opioid agonists on, 85
Affective disorders, role of opioid peptides in, 92
Amino acid neurotransmitters, interaction with opioids, 60
Analgesia, assessment in enkephalin analogues, 6
—opioid, 89
Analgesics, narcotic, correlation of binding and pharmacological data, 34
Antrum, gastric, β-endorphin-related peptides in, 29
ATWEH S F & KUHAR M J: Distribution and physiological significance of opioid receptors in the brain, 47–52

B

BARNARD E A & DEMOLIOU-MASON C: Molecular properties of opioid receptors, 37–45
Behavioural effects of opioid peptides, 89–94
BESSER G M, *see* CLEMENT-JONES V, 95
Biographical notes on contributors, 101–103
BLOOM F E, *see* KOOB G F, 89
Brain, distribution of β-endorphin-related peptides in, 28
—opioid action in, electrophysiological analysis, 59–64
——receptor binding in, regional distribution, 47
——receptors in, autoradiographic localization, 48
—prodynorphin, 18
—proenkephalin, 18
Brain-stem, opioid receptors and peptides, 77

C

Calcium, effect on opiates, 53
Calcium–adenylate cyclase, effect of opiates on, 57
Calcium–guanylate cyclase, effect of opiates on, 57
Circulatory system, opioid peptide interactions in, 77, 80–82
CLEMENT-JONES V & BESSER G M: Clinical perspectives in opioid peptides, 95–100
Contributors, biographical notes on, 101–103
CUELLO A C: Central distribution of opioid peptides, 11–16

D

DEMOLIOU-MASON C, *see* BARNARD E A, 37
Disulphide groups, role in ligant–opioid receptor interactions, 38
Drug dependence, opiate involvement, 98
DUGGAN A W: Electrophysiology of opioid peptides and sensory systems, 65–70
Dynorphins, biogenesis, 17

E

EGAN T M, *see* NORTH R A, 71
Endocrine tumours, opioid peptide involvement, 98, 99
β-Endorphin, 5–9
—distribution in brain, 28
——in gastric antrum, 29
——in human plasma, 96
——in pancreas, 29
——in pituitary, 25–28
Endorphins, distribution in man, 95
—action in adrenal medulla, 74
——on sympathetic and parasympathetic neurones, 71, 72
—analogues eliciting analgesia, 6
——structure–activity relationships, 5
—biogenesis, 17
—distribution in man, 95
——subcellular, 11
—effect on afferent neurones, 71
——on retina and olfactory bulb, 69
——on spinal neurones, 65
—inactivation, 22
—neurohypophyseal, in hypertension, 80
—δ-opioid receptor selectivity, 7, 9
—release, 20
Enkephalinase, 23
Enkephalinergic pathways in basal ganglia, 13
—synapses in spinal cord, 14
Enkephalin-like and morphine-like structures, correlation, 8
Enkephalin-peptide synthesis, control, 19

G

Ganglia, basal, enkephalinergic pathways in, 13
—effect of opioids in, 71
Gonadotrophins, effect of opioids on, 85
GROSSMAN A & REES L H: The neuroendocrinology of opioid peptides, 83–88
Growth hormone, effect of opiates and opioid peptides on, 84
Guanosine 5′-triphosphate, effect on ligand–opioid receptor interactions, 38

H

HENDERSON G: Electrophysiological analysis of opioid action in the central nervous system, 59–64
Hippocampus, effect of opioid peptides on, 69
—pyramidal cells, opioid-mediated excitation, 61
HUGHES J: Biogenesis, release and inactivation of enkephalins and dynorphins, 17–24
—& KOSTERLITZ H W: Introduction to symposium, 1–3
Hypertension, opioid peptides in, 80

K

KOOB G F & BLOOM F E: Behavioural effects of opioid peptides, 89–94
KOSTERLITZ H W, *see* HUGHES J, 1
—*see* PATERSON S J, 31
KUHAR M J, *see* ATWEH S F, 47

L

[Leu]enkephalin, 5–9
Ligand binding sites, affinity labelling, 43
Ligand–opioid receptor interactions, 1, 37, 38, 41
Luteinizing-hormone-releasing hormone, effect of opiates on, 85

M

McQUEEN D S: Opioid peptide interactions with respiratory and circulatory systems, 77–82
Metal ions, effect on ligand–opioid receptor interactions, 38
[Met]enkephalin, 5–9
MILLER R J, *see* WEST R E, 53
MORLEY J S: Chemistry of opioid peptides, 5–10
Morphine, effect on respiratory neurones and neurotransmitters, 79

N

Nalorphine, analgesic effect, 31
Naloxone, effect on pituitary hormone secretion, 99
——on prolactin, 83
——on spinal cord, 67–69
—learning and memory actions, 90
—respiratory effects, 78, 79
Narcotic dependence, opiate involvement, 98
Nervous system, central, opioid action in, electrophysiological analysis, 59–64
——enteric, action of opioid peptides on, 72
Neuroeffector junctions, action of opioid peptides on, 72
—transmission, effect of opioid peptides on, 73
Neuroendocrine systems, opioid receptors associated with, 50
Neurones, efferent, actions of opioid peptides in, 71
—enkephalin-containing, cellular biology, 11
—responses to opioids, 59–64
Nomenclature, 1, 5
NORTH R A & EGAN T M: Actions and distributions of opioid peptides in peripheral tissues, 71–75

O

Olfactory bulb, effect of enkephalins on, 69
Opiates, analgesic role, 99
—calcium antagonism, 53
—cAMP antagonism, 55
—cell response, 53
—effects on adenylate cyclase, 57
——on cardiovascular system, 80
——on learning, 90
——on memory, 90
——on protein phosphorylation, 58
—hedonic actions, 90
—respiratory depressant effect, 77
—second messengers, 53
Opioid ligands, 1, 32, 37, 38, 41
——inhibitory potencies, 32
—peptides, *see* Peptides, opioid.
—receptors, agonists and antagonists, 89
——associated with limbic structures, 50
————with neuroendocrine systems, 50
————with sensory systems, 48
——binding characteristics, 38
——biochemical characterization, 31
——classification, 31–36
——in brain, autoradiographic localization, 48
————regional distribution, 47

INDEX TO NUMBER 1

A

Acupuncture analgesia, mediation by opioid peptides, 97
Adenosine 3′5′ cyclic monophosphate, effect on opiates, 55
Adrenal medulla, enkephalin in, 74
Adrenocorticotrophic hormone, effect of opioid agonists on, 85
Affective disorders, role of opioid peptides in, 92
Amino acid neurotransmitters, interaction with opioids, 60
Analgesia, assessment in enkephalin analogues, 6
—opioid, 89
Analgesics, narcotic, correlation of binding and pharmacological data, 34
Antrum, gastric, β-endorphin-related peptides in, 29
ATWEH S F & KUHAR M J: Distribution and physiological significance of opioid receptors in the brain, 47–52

B

BARNARD E A & DEMOLIOU-MASON C: Molecular properties of opioid receptors, 37–45
Behavioural effects of opioid peptides, 89–94
BESSER G M, *see* CLEMENT-JONES V, 95
Biographical notes on contributors, 101–103
BLOOM F E, *see* KOOB G F, 89
Brain, distribution of β-endorphin-related peptides in, 28
—opioid action in, electrophysiological analysis, 59–64
——receptor binding in, regional distribution, 47
——receptors in, autoradiographic localization, 48
—prodynorphin, 18
—proenkephalin, 18
Brain-stem, opioid receptors and peptides, 77

C

Calcium, effect on opiates, 53
Calcium–adenylate cyclase, effect of opiates on, 57
Calcium–guanylate cyclase, effect of opiates on, 57
Circulatory system, opioid peptide interactions in, 77, 80–82
CLEMENT-JONES V & BESSER G M: Clinical perspectives in opioid peptides, 95–100
Contributors, biographical notes on, 101–103
CUELLO A C: Central distribution of opioid peptides, 11–16

D

DEMOLIOU-MASON C, *see* BARNARD E A, 37
Disulphide groups, role in ligant–opioid receptor interactions, 38
Drug dependence, opiate involvement, 98
DUGGAN A W: Electrophysiology of opioid peptides and sensory systems, 65–70
Dynorphins, biogenesis, 17

E

EGAN T M, *see* NORTH R A, 71
Endocrine tumours, opioid peptide involvement, 98, 99
β-Endorphin, 5–9
—distribution in brain, 28
——in gastric antrum, 29
——in human plasma, 96
——in pancreas, 29
——in pituitary, 25–28
Endorphins, distribution in man, 95
—action in adrenal medulla, 74
——on sympathetic and parasympathetic neurones, 71, 72
—analogues eliciting analgesia, 6
——structure–activity relationships, 5
—biogenesis, 17
—distribution in man, 95
——subcellular, 11
—effect on afferent neurones, 71
——on retina and olfactory bulb, 69
——on spinal neurones, 65
—inactivation, 22
—neurohypophyseal, in hypertension, 80
—δ-opioid receptor selectivity, 7, 9
—release, 20
Enkephalinase, 23
Enkephalinergic pathways in basal ganglia, 13
—synapses in spinal cord, 14
Enkephalin-like and morphine-like structures, correlation, 8
Enkephalin-peptide synthesis, control, 19

G

Ganglia, basal, enkephalinergic pathways in, 13
—effect of opioids in, 71
Gonadotrophins, effect of opioids on, 85
GROSSMAN A & REES L H: The neuroendocrinology of opioid peptides, 83–88
Growth hormone, effect of opiates and opioid peptides on, 84
Guanosine 5′-triphosphate, effect on ligand–opioid receptor interactions, 38

H

HENDERSON G: Electrophysiological analysis of opioid action in the central nervous system, 59–64
Hippocampus, effect of opioid peptides on, 69
—pyramidal cells, opioid-mediated excitation, 61
HUGHES J: Biogenesis, release and inactivation of enkephalins and dynorphins, 17–24
—& KOSTERLITZ H W: Introduction to symposium, 1–3
Hypertension, opioid peptides in, 80

K

KOOB G F & BLOOM F E: Behavioural effects of opioid peptides, 89–94
KOSTERLITZ H W, *see* HUGHES J, 1
—*see* PATERSON S J, 31
KUHAR M J, *see* ATWEH S F, 47

L

[Leu]enkephalin, 5–9
Ligand binding sites, affinity labelling, 43
Ligand–opioid receptor interactions, 1, 37, 38, 41
Luteinizing-hormone-releasing hormone, effect of opiates on, 85

M

McQUEEN D S: Opioid peptide interactions with respiratory and circulatory systems, 77–82
Metal ions, effect on ligand–opioid receptor interactions, 38
[Met]enkephalin, 5–9
MILLER R J, *see* WEST R E, 53
MORLEY J S: Chemistry of opioid peptides, 5–10
Morphine, effect on respiratory neurones and neurotransmitters, 79

N

Nalorphine, analgesic effect, 31
Naloxone, effect on pituitary hormone secretion, 99
——on prolactin, 83
——on spinal cord, 67–69
—learning and memory actions, 90
—respiratory effects, 78, 79
Narcotic dependence, opiate involvement, 98
Nervous system, central, opioid action in, electrophysiological analysis, 59–64
——enteric, action of opioid peptides on, 72
Neuroeffector junctions, action of opioid peptides on, 72
—transmission, effect of opioid peptides on, 73
Neuroendocrine systems, opioid receptors associated with, 50
Neurones, efferent, actions of opioid peptides in, 71
—enkephalin-containing, cellular biology, 11
—responses to opioids, 59–64
Nomenclature, 1, 5
NORTH R A & EGAN T M: Actions and distributions of opioid peptides in peripheral tissues, 71–75

O

Olfactory bulb, effect of enkephalins on, 69
Opiates, analgesic role, 99
—calcium antagonism, 53
—cAMP antagonism, 55
—cell response, 53
—effects on adenylate cyclase, 57
——on cardiovascular system, 80
——on learning, 90
——on memory, 90
——on protein phosphorylation, 58
—hedonic actions, 90
—respiratory depressant effect, 77
—second messengers, 53
Opioid ligands, 1, 32, 37, 38, 41
——inhibitory potencies, 32
—peptides, *see* Peptides, opioid.
—receptors, agonists and antagonists, 89
——associated with limbic structures, 50
————with neuroendocrine systems, 50
————with sensory systems, 48
——binding characteristics, 38
——biochemical characterization, 31
——classification, 31–36
——in brain, autoradiographic localization, 48
————regional distribution, 47

——interaction with endogenous ligands, 33
——ligand binding sites, affinity labelling, 43
——lipid involvement in, 43
——molecular properties, 37–45
——pharmacological characterization, 53
——purification, 43
——selectivity of enkephalins, 7, 9
——solubilization, 42

P

Pain and opioid peptide release, 21
—effect of opioid peptides in, 97
Pancreas, β-endorphin-related peptides in, 29
PATERSON S J, ROBSON L E & KOSTERLITZ H W: Classification of opioid receptors, 31–36
Peptides, β-endorphin, in pituitary, brain, pancreas and antrum, 25–30
—enkephalin, biosynthesis, 19
—opioid, action in central nervous system, electrophysiological analysis, 59–64
————on enteric nervous system, 72
————on neuroeffector junctions, 72
——actions and distributions in peripheral tissues, 71–75
——analgesic role, 97
——behavioural effects, 89–94
——binding sites, 32, 34, 35, 37
——chemistry, 5–10
——clinical perspectives, 95–100
——distribution, central, 11–16
——effect on hippocampus, 69
————on learning, 90
————on memory, 90
——electrophysiology, 65–70
——interaction with amino acid transmitters, 60
————with endogenous ligands, 33, 37
————with respiratory and circulatory systems, 77–82
——localization, immunohistochemical, 11
——neuroendocrinology, 83–88
——nomenclature, 1, 5
——opiate effects, 89
——psychopathological effects, 91, 98
——relation to psychiatric diseases, 91, 98
——release, 20–22
————steroid-modulated, 22
——role in affective disorders, 92
————in schizophrenia, 92
——structures, 5
—proopiocortin derived, effect on opioid ligands, 34
Pituitary, distribution of β-endorphin-related peptides in, 25–28
—hormones, posterior, effect of opioids on, 86
——secretion, role of opioid peptides, 99
—tumours, opioid peptide involvement in, 98
Prodynorphin, brain, 18
—derived peptides, effect on opioid ligands, 34
Proenkephalin, brain, 18
—derived peptides, effect on opioid ligands, 34
Proenkephalin-A, biogenesis, 17
Prolactin, effect of opioid peptides on, 83
Proopiocortin-derived peptides, effect on opioid ligands, 34
Proopiomelanocortin, 17, 19
Protein phosphorylation, response to opiates, 57
Psychopathological effects of opioid peptides, 91, 98

R

Receptors, opioid, *see* Opioid receptors.
REES L H, *see* GROSSMAN A, 83
Respiratory system, opioid peptide interactions in, 77–80
Retina, effect of enkephalins on, 69
ROBSON L E, *see* PATERSON S J, 31

S

Schizophrenia, role of opioid peptides in, 92, 98
Sensory systems, associated opioid receptors, 48
Shock, cardiovascular, effect of naloxone in, 80
SMYTH D G: β-Endorphin and related peptides in pituitary, brain, pancreas and antrum, 25–30
Spinal cord, effect of naloxone, 67–69
——effects of enkephalins on neurones, 65
——enkephalinergic synapses in, 14
——opioid receptors in, 48
Stress and opioid peptide release, 21

T

Thalamus, opioid receptors in, 49
Thiol groups, role in ligand–opioid receptor interactions, 38
Thyrotrophin, effect of opioids on, 85

V

Vasopressin, effect of opioids on, 86

W

WEST R E & MILLER R J: Opiates, second messengers and cell response, 53–58

INDEX TO NUMBER 2

A

Abortion, spontaneous, due to chlamydial infection, 142
Antigens, chlamydial, 112, 113
——single-serotype tests, 194–195
Arthritis, aetiology, relation to chlamydial infection, 168–174
—association with bowel infection, 172
——with genital tract infection, 168
——with psittacosis, 168, 172
——with trachoma, 172
—chlamydial, differentiation from gonococcal arthritis, 171
——in animal models, 172
—gonococcal, differentiation from chlamydial arthritis, 171
—reactive, antibody studies, 170
——chlamydial infection in, 169
——clinical features, 169
——due to genital tract infection, 168
——genetic factors, 169
——influence of antibiotic therapy on development, 171
——isolation of *C. trachomatis* in, 169, 170
——serology, 196
——sexually acquired, 168–174

B

Bartholin's glands, *C. trachomatis* infection, 140
Bedsoniae, 109
Biographical notes on contributors, 204–206
BOLTON J P & DAROUGAR S: Perihepatitis, 159–162

C

Cervix, chlamydial infection, 124, 138, 139
————antibody response, 196
—dysplasia, *C. trachomatis* antibodies in, 197
—intraepithelial neoplasia and cancer, relation to *C. trachomatis* infection, 141
Chlamydia psittaci as agent of psittacosis, 163
——classification, 109
——culture, 181, 182
——eye infections, animal models, 175–176, 190
——genital tract infection, animal models, 178
——infections, laboratory diagnosis, 126
—*trachomatis* and lymphogranuloma venereum, 151–154
——as cause of perihepatitis, 160
——cervical infection, 124, 138, 139
——classification, 109
——culture, 181
————in lower genital tract infection, 140
——eye infections, animal models, 175, 189
——fallopian tube infection, 146
——genital tract infection, animal models, 177
——in non-gonococcal urethritis, 133–137
——L1–L3 serotypes and lymphogranuloma venereum, 151, 155
——neonatal infections, serology, 197
——respiratory tract infection, animal models, 176
——role in primary and reactive arthritis, 171
Chlamydiaceae, 109
Chlamydiae, carbohydrate antigens, 112
—cell culture, 181
—classification, 109
—complement-fixation test, 194
—culture specimens, collection and storage, 181
—detection by direct examination of smears, 183–185
——by isolation and culture, 181–183
—development, 110
—immunoabsorbent assay test, enzyme-linked, 195
—immunochemistry, 112
—immunofluorescence tests, indirect, 194
—isolation, factors affecting, 182
—protein antigens, 113
—radioimmunoassay, 195
—serology, 194–200
—staining techniques, 182, 184–185
—structure, 110
—subgroups, 109
Chlamydial infection and Crohn's disease, 155–158
——animal models, 175–180
——antibody responses, 187
——association with arthritis, 168–174
——female genital tract, 138–144
————clinical features, 139–140
————complications, 141
————diagnosis, 140
————serological responses, 196
————treatment, 142
——future research, 201–203
——immune responses, 187–193
——in neonates and older children, 128–132
————epidemiological aspects and their prevention, 132
————serology, 197
——in proctitis, 155–158
——latency and persistence, 188
——male genital tract, 133–137
————laboratory diagnosis, 136
————treatment, 136
——nasopharyngeal, in infants, 130
——ocular, immune responses, 188–191
—salpingitis, 145–150
Chlamydozoaceae, 109
Colitis, ulcerative, and chlamydial infection, 157
Complement-fixation test for *Chlamydia* antibodies, 194
Conjunctivitis, chlamydial, diagnosis, 129
——in neonates, 128
——treatment and prophylaxis, 130
—inclusion, 124
——guinea-pig, use of agent in animal models 175, 178
——neonatal, 123
—neonatal, epidemiology, 128
—of older children, chlamydial, 129
Contributors, biographical notes on, 204–206
Crohn's disease, chlamydial infection and, 155–158
Curtis–Fitz-Hugh syndrome, 159–162
——serology, 197

D

DAROUGAR S & JONES B R: Trachoma, 117–122
—*see* BOLTON J P, 159

E

Epididymitis complicating non-gonococcal urethritis, 135
—serology, 196
EVANS R T & WOODLAND R M: Detection of chlamydiae by isolation and direct examination, 181–186
Eye, chlamydial infections, animal models, 175–176, 189–192
————immune responses, 188–191

F

Fallopian tubes, *C. trachomatis* infection and infertility, 197
——chlamydial infection, 145–150
FORSEY T, *see* TREHARNE J D, 194

G

Genital tract, chlamydial infection, animal models, 177, 192
————immune responses, 191
——female, chlamydial infection, 138–144
————clinical features, 139–140
————complications, 141
————diagnosis, 140
————serological responses, 196
————treatment, 142
——male, chlamydial infection, laboratory diagnosis, 136
————serological responses, 196
————treatment, 136
————histology, 133
————infection, 133–137

H

HARE M J & THIN R N: Chlamydial infection of the lower genital tract of women, 138–144
HOBSON D, REES E & VISWALINGAM N D: Chlamydial infections in neonates and older children, 128–132

I

Immune responses and chlamydial infections, 187–193
Immunoabsorbent assay test, enzyme-linked, for *Chlamydia*, 195
Immunofluorescence tests, indirect, for *Chlamydia* antibodies, 194
Infant, newborn, chlamydial infections, 128–132
————serology, 197
Infertility after *C. trachomatis* infection, 142, 197
Intra-uterine contraceptive devices, chlamydial infection due to, 145, 149

INDEX TO NUMBER 2

J

JOHNSON A P, *see* WOODLAND, R M, 175
JONES B R: Chlamydial disease. Introduction to symposium, 107
—& TAYLOR-ROBINSON D: Observations on and future trends in chlamydial research, 201–203
—*see* DAROUGAR S, 117

K

KEAT A, THOMAS B J & TAYLOR-ROBINSON D: Chlamydial infection in the aetiology of arthritis, 168–174
Keratoconjunctivitis, chlamydial, 124, 125
—feline, use of agent in animal models, 176, 179

L

Lymphadenopathy in lymphogranuloma venereum, 152
Lymphogranuloma venereum, 110, 123
——and *C. trachomatis* infection, 151–154, 155
——antibody studies, 153
——association with arthritis, 168
——clinical manifestations, 152
——diagnosis, laboratory methods, 153
——epidemiology, 151
——extragenital infections in, 153
——historical background, 151
——serological response, 198
——systemic complications, 153
——treatment, 154

M

MACFARLANE J T & MACRAE A D: Psittacosis, 163–167
MACRAE A D, *see* MACFARLANE J T, 163
MÅRDH P-A, *see* WESTRÖM L, 145
MONNICKENDAM M A & PEARCE J H: Immune responses and chlamydial infections, 187–193
Mouse pneumonitis due to *C. trachomatis*, 176, 177
MUNDAY P E & TAYLOR-ROBINSON D: Chlamydial infection in proctitis and Crohn's disease, 155–158

N

Nasopharynx, chlamydial infection in infants, 130
Neisseria gonorrhoeae in perihepatitis, 160
Nucleic acids in chlamydiae, 109

O

Ophthalmia, chlamydial, adult, *see* Paratrachoma
—neonatorum, chlamydial, 138
ORIEL J D & RIDGWAY G L: Genital infection in men, 133–137
Ornithosis, 123
OSOBA A O, *see* SCHACHTER J, 151

P

Paratrachoma, 123–127
—clinical features, 124
—diagnosis, laboratory, 125
—diagnostic features, 125
—differential diagnosis, 125
—epidemiology, 123
—immune response, 189–191
—serological response, 195
—treatment, 126
PEARCE J H, *see* MONNICKENDAM M A, 187
Perihepatitis, 159–162
—and genital tract infection, 160
—*C. trachomatis* as causative organism, 160
—clinical picture, 160
—diagnosis, 161
—epidemiology, 160
—*N. gonorrhoeae* involvement in, 160
—serology, 197
—transmission, 160
—treatment, 161
Pneumonia and chlamydial infection in infants, 130
—due to psittacosis, 164
Proctitis and proctocolitis in lymphogranuloma venereum, 153
—chlamydial infection in, 155–158
—in women, and *C. trachomatis* infection, 155
—non-gonococcal, in male homosexuals, *C. trachomatis* involvement, 156
Prostatitis, serology, 196
Psittacosis, 163–167
—antibody studies, 165
—clinical features, 164
—complement-fixation test for, 112
—diagnosis, 165
—differential diagnosis, 166
—epidemiology, 163
—extrapulmonary manifestations, 164
—management, 166
—mortality, 166
—pathology, 164
—polyarthralgia in, 172
—prevention, 167
—radiographic features, 165
—serology, 198

R

Radioimmunoassay test for *Chlamydia*, 195
Rectum, chlamydial infection, 155–158
REES E, *see* HOBSON D, 128
Reiter's syndrome, isolation of *C. trachomatis* in, 168, 170
Respiratory tract, chlamydial infection, animal models, 176–177
RIDGWAY G L, *see* ORIEL J D, 133

S

Sacro-iliitis, association with prostatitis, 172
——with salpingitis, 172
Salpingitis and sacro-iliitis, 172
—chlamydial, 145–150
——clinical aspects, 147
——diagnosis, 148
——epidemiology, 146
——sequelae, 148
——treatment, 148
SCHACHTER J & OSOBA A O: Lymphogranuloma venereum, 151–154
Spondylitis, association with prostatitis, 172

T

TAYLOR-ROBINSON D, *see* JONES B R, 201
—*see* KEAT A, 168
—*see* MUNDAY P E, 155
THIN R N, *see* HARE M J, 138
THOMAS B J, *see* KEAT A, 168
—*see* TREHARNE J D, 194
Trachoma, 117–122
—association with *Chlamydia*, 117
—blinding and non-blinding, recognition, 121
——complications, scoring of, 119
—clinical course, MacCallan's classification, 118
——features, 117, 118
——scoring methods, 118
—complications, 118, 119
—control, 121
—diagnosis, 119
——laboratory methods, 119
—differential diagnosis, 119
—distribution, 120
—epidemiology, 109, 120
—immune response, 188–191
—immunization, 109
—incidence, 120
—incubation period, 117
—inflammatory response, scoring classification of intensity, 118
—prevalence, 120
—serological response, 195
—sexual transmission, 123, 124
—symptoms and signs, 117
—transmission, 120
—treatment, 121
—vaccine, 122
TREHARNE J D, FORSEY T & THOMAS B J: Chlamydial serology, 194–200
TRIC agents, 109
TUFFREY M, *see* WOODLAND R M, 175

U

Urethra, female, *C. trachomatis* in, 140
—stricture complicating non-gonococcal urethritis, 135
Urethritis, non-gonococcal, 133–137
——associated complications, 135
——association with chlamydial infection, 168
——*C. trachomatis* in, 133–137
——chlamydial and non-chlamydial, differentiation, 134
——laboratory diagnosis, 136
——serological responses, 196
——symptoms and signs, 134
——treatment, 136
—post-gonococcal, *C. trachomatis* in, 135
——serological responses, 196

V

VISWALINGAM N D, WISHART M S & WOODLAND R M: Adult chlamydial ophthalmia (paratrachoma), 123–127
—*see* HOBSON D, 128

W

WARD M E: Chlamydial classification, development and structure, 109–115
WESTRÖM L & MÅRDH P-A: Chlamydial salpingitis, 145–150
WISHART M S, *see* VISWALINGAM N D, 123
WOODLAND R M, JOHNSON A P & TUFFREY M: Animal models of chlamydial infection, 175–180
—*see* EVANS R T, 181
—*see* VISWALINGAM N D, 123

INDEX TO NUMBER 3

A

Adenosine monophosphate levels, action of prostacyclin and thromboxanes on, 233
———effect of prostaglandins on, 243
Airways, efffect of leukotrienes on, 256
Angina pectoris, effect of prostacyclin in, 282
Arachidonic acid, 210
——lipoxygenase metabolism, 219, 220
——metabolism, 277
——metabolites, immunoregulatory activity and role in inflammation, 243–248
——oxidation via cyclo-oxygenase pathway, 214, 215
Arachidonic acid–thromboxane pathway, clinical aspects, 289–295
Aspirin, effect on cyclo-oxygenase activity, 265, 290
Asthma, effect of prostacyclin in, 282
Atherosclerosis, lipid hydroperoxide levels in, 279

B

BAKHLE Y S: Synthesis and catabolism of cyclo-oxygenase products, 214–218
Biographical notes on contributors, 296–298
BLACKWELL G J & FLOWER R J: Inhibition of phospholipase, 260–264
BLAIR I A: Measurement of eicosanoids by gas chromatography and mass spectrometry, 223–226
Bone, prostaglandins in, 247
Bradykinin, interaction with prostaglandins, 239
BRAY M A: Pharmacology and pathophysiology of leukotriene B_4, 249–254
Bronchopulmonary system, action of prostacyclin and thromboxanes on, 235
BUNTING S, MONCADA S & VANE J R: Prostacyclin–thromboxane A_2 balance: pathophysiological and therapeutic implications, 271–276

C

Cardiopulmonary by-pass, prostacyclin in, 287
Cardiovascular system, action of leukotrienes on, 257
——action of prostacyclin and thromboxanes on, 233
Cartilage, prostaglandins in, 247
Cells, destruction and protection, action of prostacyclin and thromboxanes in, 236
Circulation, extracorporeal, use of prostacyclin in, 282, 285–288
Contributors, biographical notes on 296–298
CRAWFORD M A: Background to essential fatty acids and their prostanoid derivatives, 210–213
Cyclo-oxygenase, inihibition, 265–269
——inhibition in vitro, 265
——in vivo by anti-inflammatory drugs, 265
———effects, 266
—inhibitors, therapeutic potential, 268
——toxicity, 267
—products, catabolism, 216
——levels, physiological factors affecting, 217
——measurement by bioassay and radioimmunoassay, 227–231
———by gas chromatography and mass spectrometry, 223–226
——pathological factors affecting, 217
——synthesis, 214

D

Diabetes and prostacyclin–thromboxane A_2 imbalance, 273
Dihydroxy acids, 255
DOLLERY C T, *see* LEWIS P J, 281

E

Eicosanoids, measurement by bioassay and radioimmunoassay, 227–231
——by gas chromatography and mass spectrometry, 223–226
—synthesis, origin of substrate for, 260
Eicosapentaenoic acid, 274
Extracorporeal circulation, use of prostacyclin in, 282, 285–288

F

Fatty acids, essential, and their prostanoid derivatives, 210–213
———link with prostaglandins, 211
———metabolism, 210, 211
FLOWER R J, *see* BLACKWELL G J, 260

G

Gastrointestinal function, action of prostacyclin and thromboxanes on, 236

H

Haemodialysis, prostacyclin in, 286
Haemoperfusion, charcoal, use of prostacyclin in, 285
Heart valves, prosthetic, effectiveness of arachidonic acid–thromboxane A_2 pathway manipulators in, 293
HIGGS G A & VANE J R . Inhibition of cyclo-oxygenase and lipoxygenase, 265–270
Histamine, interaction with prostaglandins, 239
15-Hydroxyprostaglandin dehydrogenase, 216
Hypertension of pregnancy, efffect of prostacyclin in, 282
—pulmonary, effect of prostacyclin in, 282

I

Immune response, role of prostaglandins, 243–248
Inflammation, contribution of cyclo-oxygenase products to, 267
—interactions between prostaglandins, leukotrienes and other mediators, 239–242
—prostaglandin source in, 244
—role of arachidonic acid metabolites, 243–248
——of prostacyclin and thromboxanes in, 235

K

Kidney function, action of prostacyclin and thromboxanes on, 235

L

LANDS W E M, *see* WARSO M A, 277
Leucocytes, effects of leukotrienes on, 246
Leukotriene B_4, biological generation, 250
—biological role, 253
—chemotactic properties, 253
—discovery and definition, 249
—drug manipulation, 253
—effects on isolated cell populations, 250
——on smooth muscle, 252
—intracellular and membrane effects, 251
—measurement, 249
—metabolism, 249
—pharmacology and pathophysiology, 249–254
—properties in vitro, 251
——in vivo, 252
Leukotrienes, action on cardiovascular system, 257
——on microvasculature, 257
——on smooth muscle, 252, 256
—and slow-reacting substances, 255
—biological actions, 256
—biosynthetic pathway from arachidonic acid, 220, 221
—bronchoconstrictor properties, 256
—C-6 amino-acid-substituted, 255
—derivation from essential fatty acids, 211
—effect on mucus secretion, 257
——on leucocytes, 246
—interactions with prostaglandins, 241
—pharmacology, 255–259
LEWIS G P: Immunoregulatory activity of metabolites of arachidonic acid and their role in inflammation, 243–248
LEWIS P J & DOLLERY C T: Clinical pharmacology and potential of prostacyclin, 281–284
Linoleic acid, 210
Linolenic acid, 210
Lipid peroxidation in relation to prostacyclin and thromboxane physiology and pathophysiology, 277–280
—peroxides, measurement, 280
Lipoxygenases, animal, 220
—inhibition, 268
—inhibitors, therapeutic potential, 268
—measurement by bioassay and radioimmunoassay, 227–231
——by gas chromatography and mass spectrometry, 223–226
—mode of action, 219
—pathways, 219–222
—plant, 219
Lymphocyte function, effect of prostaglandins on, 245
Lysosomal enzymes, effects of prostaglandins on release, 246

M

MITCHELL J R A: Clinical aspects of the arachidonic acid–thromboxane pathway, 289–295
MONCADA S & VANE J R: Prostacyclin, thromboxane and leukotrienes. Introduction to symposium, 209
—*see* BUNTING S, 271
—*see* WHITTLE, B J R, 232

MORRIS H R, *see* TAYLOR G W, 219
Mucus secretion, effect of leukotrienes on, 257
Myocardial infarction, clinical effectiveness of arachidonic acid–thromboxane A_2 pathway manipulators, 291

P

Peptides, complement-derived, interactions with prostaglandins, 240
Phosphatides, structure, 260
Phospholipase, enzymic properties, distribution, 261
—implication in pathological states, 263
—inhibition, 260
—inhibitors, glucocorticoid-induced, 262
—products, non-eicosanoid, biological activities, 261
Phospholipase A, inhibitors, 261
Phospholipase C, inhibitors, 262
PIPER P J: Pharmacology of leukotrienes, 255–259
Platelets, action of prostacyclin and thromboxanes on, 232
—aggregation, and charcoal perfusion with prostacyclin, 285
——by prostaglandin endoperoxides and thromboxane A_2, 272
——effect of hydroperoxides on, 279
—consumption syndromes, effect of prostacyclin, 282
Prostacyclin, action on bronchopulmonary system, 235
——on cAMP levels, 233
——on cardiovascular system, 233
——on gastrointestinal function, 236
——on kidney function, 235
——on platelets, 233
—and cardiopulmonary by-pass, 287
—and extracorporeal circulation, 282, 285–288
—and haemodialysis, 286
—biosynthesis, 271
—clinical pharmacology, 281–284
—in pathological conditions, 272
—measurement by bioassay and radioimmunoassay, 227–231
——by gas chromatography and mass spectrometry, 223–226
—pharmacodynamic effects in man, 281
—pharmacokinetics, 281
—pharmacological interactions with thromboxanes, 232–238
—physiology and pathophysiology, relation to lipid peroxidation, 277–280
—production, stimulation, 275
—role in cell destruction and protection, 236
——in inflammation, 235
—side-effects, 282
—synthase, 271
——inhibition, 274
————by hydroperoxides, 278
—therapeutic prospect, 283
Prostacyclin–thromboxane A_2 balance: pathophysiological and therapeutic implications, 271–276
Prostacyclin:thromboxane A_2 ratio, dietary manipulation, 274
Prostaglandin H synthase, activation by lipid peroxidation, 277
——inactivation by hydroperoxides, 278
Prostaglandins and control of lymphocyte function, 245
—derivation from essential fatty acids, 211
—effects on lysosomal enzyme release, 246
—endoperoxides in platelet aggregation, 272
—in bone, 247
—in cartilage, 247
—interactions with complement-derived peptides, 240
——with histamine and bradykinin, 239
——with leukotrienes, 241
—isolation, 210
—measurement by bioassay and radioimmunoassay, 227–231
——by gas chromatography and mass spectrometry, 223–226
—role in inflammatory response, 243
—source in inflammation, 244
—synthesis and catabolism, 214–218
——from precursors, routes, 212
——inhibitors, 265
Prostanoid derivatives of essential fatty acids, 210–213
Purpura, thrombocytopenic, and prostacyclin–thromboxane A_2 imbalance, 273
——effect of prostacyclin, 282

S

SALMON J A: Measurement of eicosanoids by bioassay and radioimmunoassay, 227–231
Stroke, clinical effectiveness of arachidonic acid–thromboxane A_2 pathway manipulators, 292

T

TAYLOR G W & MORRIS H R: Lipoxygenase pathways, 219–222
Thrombo-embolism, venous, effectiveness of arachidonic acid–thromboxane A_2 pathway manipulators, 292
Thrombosis and prostacyclin–thromboxane A_2 imbalance, 272
—effectiveness of arachidonic acid–thromboxane A_2 pathway manipulators, 292, 293
Thromboxane, physiology and pathophysiology, 277–280
—synthase, 271
——inhibition, 273
—synthesis, effect of hydroperoxides on, 278
Thromboxane–arachidonic acid pathway, clinical aspects, 289–295
Thromboxane A_2, action on bronchopulmonary system, 235
——on cAMP levels, 233
——on cardiovascular system, 233
——on gastrointestinal function, 236
——on kidney function, 235
——on platelets, 232
—in pathological conditions, 272
—in platelet aggregation, 272
—measurement by bioassay and radioimmunoassay, 227–231
——by gas chromatography and mass spectrometry, 223–226
—pharmacological interactions with prostacyclin, 232–238
—role in cell destruction and protection, 236
——in inflammation, 235
—synthesis and catabolism, 214–218
Thromboxane A_2–prostacyclin balance: pathophysiological and therapeutic implications, 271–276
Thromboxane A_2:prostacyclin ratio, dietary manipulation, 274

U

Uraemia and prostacyclin–thromboxane A_2 imbalance, 273
Uraemic syndrome, haemolytic, effect of prostacyclin in, 282

V

VANE J R, *see* BUNTING S, 271
—*see* HIGGS G A, 265
—*see* MONCADA S, 209
Vascular disease, peripheral, effect of prostacyclin in, 282

W

WARSO M A & LANDS W E M: Lipid peroxidation in relation to prostacyclin and thromboxane physiology and pathophysiology, 277–280
WESTON M J: Prostacyclin and extracorporeal circulation, 285–288
WHITTLE B J R & MONCADA S: Pharmacological interactions between prostacyclin and thromboxanes, 232–238
WILLIAMS T J: Interactions between prostaglandins, leukotrienes and other mediators of inflammation, 239–242

INDEX TO NUMBER 4

A

Abortion, spontaneous, after amniocentesis, 316
Acetylcholinesterase, physiology, 375
—use in prenatal diagnosis of neural tube defects, 376
Adenosine deaminase deficiency, pathophysiology and prenatal diagnosis, 400, 401
Alleles of disease, detection by linkage, 345
Alphafetoprotein, concentration measurement, technical and diagnostic problems, 374
—maternal serum, differential diagnosis of abnormalities detected by screening, 367
———impact of screening in West of Scotland, 369
———screening for reduction of anencephalic and spina bifida births, 365–372
———use of screening in high-risk groups, 371
—measurement, predictive power, 375
—physiology, 373
—use in prenatal diagnosis of anencephaly and spina bifida, 373
—values, frequency distribution at 16–18 weeks' gestation, 366
Amino acid disorders, prenatal diagnosis, 383
Amniocentesis, hazards, 311, 316
—in diagnosis of inherited metabolic disorders, 379, 380
—in second trimester, and termination of pregnancy, 315–321
—indications, 316
—perinatal morbidity and mortality due to, 316
—technique, 315
Amniotic fluid cells, culture, long-term, 350
———culture, short-term and rapidly adhering cells, 350
———numbers and changes during gestation in normal and abnormal pregnancies, 349
———origins, 348
———types and culture, 348–354
———uncultured, use for prenatal diagnosis, 349
———use in prenatal diagnosis, 348
——tests for neural tube defects, 373–377
——volume changes, ultrasonic detection, 329
Anencephalic births, reduction by maternal serum alphafetoprotein screening, 365–372
Anencephaly, prenatal diagnosis, use of alphafetoprotein, 373
—ultrasonic detection, 324
Aneuploidy, fetal, recurrence risks, 359
Autosomal dominant inheritance, risk estimation in, 304
—recessive inheritance, risk estimation in, 305

B

Biographical notes on contributors, 405
Bleeding disorders, prenatal diagnosis, 392–398
Blood, fetal, sampling by fetoscopy, 333
—platelet defects, prenatal diagnosis, 396
Brain cysts, ultrasonic detection, 326
BROCK, D J H: Amniotic fluid tests for fetal neural tube defects, 373

C

C_3 deficiency, congenital, prenatal diagnosis, 403
CAMPBELL S & PEARCE J M: Ultrasound visualization of congenital malformations, 322
Carbohydrate disorders, prenatal diagnosis, 383
Cell culture in prenatal diagnosis of inherited metabolic disorders, 379, 380
Cerebellum, congenital anomalies, ultrasonic detection, 326
Chediak-Higashi syndrome, 403
Chorion biopsy in first trimester, 338–342
——applications, 341
——techniques, 339
Chromosome aberrations, familial, recurrence risks in offspring, 360
——fetal, results of screening older mothers, 358
——in fetus and in vitro, use of amniotic fluid cells, 352
—analysis, prenatal, future, 363
———impact on birth incidence of chromosome disorders, 355–364
—disorders, inheritance, risk estimation, 306
——prenatal diagnosis, 355–364
———technical problems, 362
—Robertsonian translocations, 360
Complement C_3, congenital deficiency, prenatal diagnosis, 403
Congenital malformations, ultrasound visualization, 322
Contributors, biographical notes on, 405
Counselling, genetic, *see* Genetic counselling
Cranial anomalies, ultrasonic detection, 323, 327
CRAWFURD M d'A: Ethical and legal aspects of early prenatal diagnosis, 310

D

Diagnosis, prenatal, *see* Prenatal diagnosis
DNA, recombinant technology, application to prenatal detection of inherited defects, 343
Down's syndrome, recurrence risk in later pregnancy, 359
——risk associated with increased maternal age, 355
Duchenne muscular dystrophy, detection by fetoscopy blood sampling, 334
———prenatal diagnosis, 361

E

Encephalocele, ultrasonic detection, 325
Epidermolysis bullosa, prenatal diagnosis, 353

F

FERGUSON-SMITH M A: Early prenatal diagnosis; introduction to symposium, 301
—Prenatal chromosome analysis and its impact on the birth incidence of chromosome disorders, 355
—The reduction of anencephalic and spina bifida births by maternal serum alphafetoprotein screening, 365
Fertility, risks following abortion, 320
Fetoscopy and fetal tissue sampling, 332–337
—development, 332
—diagnostic, general considerations and procedure, 332
—pregnancy outcome after, 336
Fetus, aneuploidy, recurrence risks, 359
—anomalies, ultrasound diagnosis, 322–331
—blood sampling by fetoscopy, 333, 394
—chromosome analysis, impact on birth incidence of chromosome disorders, 355–364
—examination by fetoscopy, 335
—growth, ultrasonic measurement, 323
—liver biopsy by fetoscopy, 336
—sex determination, 361
———and disclosure, legal aspect, 313
——ultrasonic determination, 327
—skin biopsy by fetoscopy, 335
——disorders, and amniotic fluid cells, 352
—structural anomalies diagnosed by ultrasound examination, 322
—tumours, ultrasonic detection, 327
Fragile-X syndrome, 361

G

Gastrointestinal anomalies, fetal, ultrasound visualization, 327
Genetic counselling and maternal disease, 307
——and prenatal diagnosis, 302–309
——and risk estimation, 304
——in pregnancy, patterns, 308
——prior to early prenatal diagnosis, 311
——problems in pregnancy, 303
——timing, 307
—disease, prevention by health education, 390
GOSDEN C M: Amniotic fluid cell types and culture, 348
Granulomatous disease, chronic, prenatal diagnosis, 403

H

Haemoglobinopathies, fetal diagnosis, 387
—first-trimester fetal diagnosis, 389
—prevention, 386–391
Haemophilia, fetal, and allied bleeding disorders, 392–398
——laboratory diagnosis, 394
——steps in diagnosis, 393
—molecular basis, 392
Haemophilia A, prenatal diagnosis, 395
Haemophilia B, prenatal diagnosis, 396
HARPER P S: Genetic counselling and prenatal diagnosis, 302
Heart, fetal anomalies, ultrasound visualization, 330
Hernia, diaphragmatic, ultrasound visualization, 327
Heterozygote detection, 386

INDEX TO NUMBER 4

HUMPHRIES S E & WILLIAMSON R: Application of recombinant DNA technology to prenatal detection of inherited defects, 343
Hydrocephaly, ultrasonic detection, 325
Hydrops fetalis, ultrasonic detection, 331

I

Icthyoses, prenatal diagnosis, 353
Immunodeficiency disorders, prenatal diagnosis, 399–404
—severe combined, clinical features and pathophysiology, 400
——prenatal diagnosis, 401
—with ataxia telangiectasia, 402
—with thrombocytopenia and eczema, 402
Inherited defects, application of recombinant DNA technology to prenatal detection, 343–347

K

Kidney, fetal anomalies, ultrasound visualization, 327
Klinefelter's syndrome, 355

L

LEVINSKY R J, *see* LINCH, D C, 399
Limb reduction deformities, ultrasound visualization, 330
LINCH D C & LEVINSKY R J: Prenatal diagnosis of immunodeficiency disorders, 399
Lipid disorders, prenatal diagnosis, 381
Liver, fetal, biopsy by fetoscopy, 336
Lymphoid system, ontogeny, 399
Lymphopenia with isolated T-cell dysfunction, 402

M

MacKENZIE I Z, *see* TURNBULL, A C, 315
Malformations, congenital, ultrasound visualization, 322–331
Maternal age effects on occurrence of fetal chromosome aberrations, 355
Metabolic disorders, inherited, prenatal diagnosis, 378–385
——prerequisite biochemical diagnosis, 378
Metabolism, inborn errors, prenatal diagnosis using amniotic fluid cells, 352
MIBASHAN R S & MILLAR D S: Fetal haemophilia and allied bleeding disorders, 392
Microcephaly, ultrasonic diagnosis, 326
MILLAR D S, *see* MIBASHAN R S, 392
MODELL B: Prevention of the haemoglobinopathies, 386
MORSMAN J M, *see* RODECK, C H, 338
Mosaicism, prenatal diagnosis, 362
Mucopolysaccharidoses, prenatal diagnosis, 382
Musculo-skeletal abnormalities in babies following amniocentesis, 317

N

Neural tube defects, amniotic fluid tests for, 373–377
——diagnosis, use of acetylcholinesterase, 376
——ultrasonic detection, 323
NICOLAIDES K N, *see* RODECK C H, 332

O

Omphalocele–gastroschisis, ultrasound visualization, 327

P

Paternal age, lack of importance in fetal chromosome aberrations, 357
PATRICK A D: Inherited metabolic disorders, 378
PEARCE J M, *see* CAMPBELL S, 322
Platelet defects, prenatal diagnosis, 396
Pregnancy, outcome after fetoscopy, 336, 396
—termination for fetal conditions, incidence, 317
——in second trimester, methods, 318
——late, hazards, 319
Prenatal diagnosis; introduction to symposium, 301
——and genetic counselling, 302–309
——early, ethical and legal aspects, 310–314
Pseudomosaicism, 362
Purine nucleoside phosphorylase deficiency, 402

R

Respiratory distress following amniocentesis, 317
RODECK C H & MORSMAN J M: First-trimester chorion biopsy, 338
—& NICOLAIDES K H: Fetoscopy and fetal tissue sampling, 332

S

Screening programmes, prenatal, 312
Sex, fetal, determination, 361
——determination and disclosure, legal aspect, 313
——ultrasonic determination, 327
Skin biopsy, fetal, by fetoscopy, 335
Spina bifida births, reduction by maternal serum alphafetoprotein screening, 365–372
——prenatal diagnosis, use of alphfetoprotein, 373
——ultrasonic detection in pregnancy, 324

T

Tay–Sachs disease, 381
Thalassaemia, prevention in Britain, 388
—traits, diagnosis, 387
TURNBULL A C & MacKENZIE I Z: Second-trimester amniocentesis and termination of pregnancy, 315
Twins, risk estimation for genetic problems, 307

U

Ultrasonography, hazards, 311
Ultrasound visualization of congenital malformations, 322–331
Urinary tract obstruction, fetal, ultrasound detection, 329

W

von Willebrand's disease, prenatal diagnosis, 396
WILLIAMSON R, *see* HUMPHRIES S E, 343
Wiskott–Aldrich syndrome, 396, 402

X

X-linked disorders, inheritance, risk estimation, 306

Printed in Great Britain by Spottiswoode Ballantyne Ltd., Colchester and London